再生元(REGN)與賽諾菲(SNY)抗炎藥年中或迎新適應症獲批

金吾財訊

2025/03/11

金吾財訊 | 再生元(REGN)與賽諾菲(SNY)在2025年美國皮膚科學會年會上公布，其IL-4/IL-13抑制劑Dupixent(達必妥)治療中重度大皰性類天皰瘡(BP)的2/3期ADEPT試驗達到全部主要及關鍵次要終點：治療組持續緩解率是安慰劑組的5倍。FDA已受理該適應症補充申請並授予優先審評，預計2025年年中獲批。Dupixent作為全球首個獲批的IL-4/IL-13雙通路抑制劑，已在7大適應症(特應性皮炎、哮喘等)覆蓋60多個國家，惠及超百萬患者。此次新適應症針對自身免疫性大皰病，其獨特的"靶向抑制+免疫調節"機制為傳統療法耐藥患者提供新選擇。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2518181927"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2518181927\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2518181927?lang=zh_TW&edition=fundamental","thumbnail":"https://static.szfiu.com/news/20210625/OTU2NGE4NGJmZTIzZDc2N2YxYmJkM2MyMjUzODQzOTQ1NzY=.jpg","is_english":false,"pubTime":"2025-03-11 17:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518181927","market":"sg","top_or_hot":-1,"title":"再生元(REGN)與賽諾菲(SNY)抗炎藥年中或迎新適應症獲批","media":"金吾財訊","content":"<html><body><p>金吾財訊 | 再生元(REGN)與<a href=\"https://laohu8.com/S/0O59.UK\">賽諾菲</a>(SNY)在2025年美國皮膚科學會年會上公布，其IL-4/IL-13抑制劑Dupixent(達必妥)治療中重度大皰性類天皰瘡(BP)的2/3期ADEPT試驗達到全部主要及關鍵次要終點：治療組持續緩解率是安慰劑組的5倍。FDA已受理該適應症補充申請並授予優先審評，預計2025年年中獲批。Dupixent作為全球首個獲批的IL-4/IL-13雙通路抑制劑，已在7大適應症(特應性皮炎、哮喘等)覆蓋60多個國家，惠及超百萬患者。此次新適應症針對自身免疫性大皰病，其獨特的\"靶向抑制+免疫調節\"機制為傳統療法耐藥患者提供新選擇。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>再生元(REGN)與賽諾菲(SNY)抗炎藥年中或迎新適應症獲批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n再生元(REGN)與賽諾菲(SNY)抗炎藥年中或迎新適應症獲批\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086022552\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">金吾財訊 </p>\n<p class=\"h-time smaller\">2025-03-11 17:21</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>金吾財訊 | 再生元(REGN)與<a href=\"https://laohu8.com/S/0O59.UK\">賽諾菲</a>(SNY)在2025年美國皮膚科學會年會上公布，其IL-4/IL-13抑制劑Dupixent(達必妥)治療中重度大皰性類天皰瘡(BP)的2/3期ADEPT試驗達到全部主要及關鍵次要終點：治療組持續緩解率是安慰劑組的5倍。FDA已受理該適應症補充申請並授予優先審評，預計2025年年中獲批。Dupixent作為全球首個獲批的IL-4/IL-13雙通路抑制劑，已在7大適應症(特應性皮炎、哮喘等)覆蓋60多個國家，惠及超百萬患者。此次新適應症針對自身免疫性大皰病，其獨特的\"靶向抑制+免疫調節\"機制為傳統療法耐藥患者提供新選擇。</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2089984988.USD","symbol_name":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","start_time":0,"source_url":"286264","article_id":"2518181927","we_media_id":"1086022552","thumbnails":["https://static.szfiu.com/news/20210625/OTU2NGE4NGJmZTIzZDc2N2YxYmJkM2MyMjUzODQzOTQ1NzY=.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518181927","pubTimestamp":1741684881,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"金吾財訊","introduction":"「金吾财讯」以精准用户需求为切入点，打造一站式港美股投资细分领域品牌。依托战略合作伙伴凤凰网财经，将港美股内容传播到全球华人圈。","home_visible":1,"id":"1086022552","head_image":"https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c"},"summary":"金吾財訊 | 再生元(REGN)與賽諾菲(SNY)在2025年美國皮膚科學會年會上公布，其IL-4/IL-13抑制劑Dupixent(達必妥)治療中重度大皰性類天皰瘡(BP)的2/3期ADEPT試驗達到全部主要及關鍵次要終點：治療組持續緩解率是安慰劑組的5倍。FDA已受理該適應症補充申請並授予優先審評，預計2025年年中獲批。Dupixent作為全球首個獲批的IL-4/IL-13雙通路抑制劑，已在7大適應症(特應性皮炎、哮喘等)覆蓋60多個國家，惠及超百萬患者。此次新適應症針對自身免疫性大皰病，其獨特的\"靶向抑制+免疫調節\"機制為傳統療法耐藥患者提供新選擇。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","SNY":"赛诺菲安万特","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4588":"碎股","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","REGN":"再生元制药公司","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","BK4007":"制药","LU1917777945.USD":"安联专题基金Cl AT Acc"},"translate_title":"Regeneron (REGN) and Sanofi (SNY) anti-inflammatory drugs will be approved for new indications mid-year or welcome","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":1,"SNY":1},"content_text":"金吾財訊 | 再生元(REGN)與賽諾菲(SNY)在2025年美國皮膚科學會年會上公布，其IL-4/IL-13抑制劑Dupixent(達必妥)治療中重度大皰性類天皰瘡(BP)的2/3期ADEPT試驗達到全部主要及關鍵次要終點：治療組持續緩解率是安慰劑組的5倍。FDA已受理該適應症補充申請並授予優先審評，預計2025年年中獲批。Dupixent作為全球首個獲批的IL-4/IL-13雙通路抑制劑，已在7大適應症(特應性皮炎、哮喘等)覆蓋60多個國家，惠及超百萬患者。此次新適應症針對自身免疫性大皰病，其獨特的\"靶向抑制+免疫調節\"機制為傳統療法耐藥患者提供新選擇。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}